Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Public Offering	Kuur	Cidal	Common Stock	Common Stock Public Offering	Common Stock Kuur	Common Stock Cidal	Additional Paid-in Capital	Additional Paid-in Capital Public Offering	Additional Paid-in Capital Kuur	Additional Paid-in Capital Cidal	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income	Treasury Stock	Total Athenex, Inc. Stockholders' Equity (Deficit)	Total Athenex, Inc. Stockholders' Equity (Deficit) Public Offering	Total Athenex, Inc. Stockholders' Equity (Deficit) Kuur	Total Athenex, Inc. Stockholders' Equity (Deficit) Cidal	Non-Controlling Interests
Beginning balance at Dec. 31, 2020	$ 165,348				$ 5				$ 901,954				$ (713,644)	$ (1,134)	$ (7,406)	$ 179,775				$ (14,427)
Beginning balance, shares at Dec. 31, 2020					4,753,310										(83,646)
Sale of common stock through ATM and ESPP	1,342								1,342							1,342
Sale of common stock through ATM and ESPP, shares					42,220
Equity consideration in connection with acquisition			$ 58,427	$ 1			$ 1				$ 58,426	$ 1						$ 58,427	$ 1
Equity consideration in connection with acquisition, shares							780,083	565
Stock-based compensation cost	8,591								8,591							8,591
Restricted stock expense	616								616							616
Stock options exercised	1,579								1,579							1,579
Stock options exercised, shares					13,971
Treasury stock repurchase	(79)														$ (79)	(79)
Disposal of non-controlling interest	16																			16
Net loss	(202,036)												(199,768)			(199,768)				(2,268)
Other comprehensive gain, net of tax	647													647		647
Ending balance at Dec. 31, 2021	34,452				$ 6				972,509				(913,412)	(487)	$ (7,485)	51,131				(16,679)
Ending balance, shares at Dec. 31, 2021					5,590,149										(83,646)
Sale of common stock		$ 17,773				$ 2				$ 17,771							$ 17,773
Sale of common stock, shares						1,766,667
Sale of common stock through ATM	9,395				$ 1				9,394							9,395
Sale of common stock through ATM shares					1,263,251
Sale of common stock through ESPP	545								545							545
Sale of common stock through ESPP shares					84,571
Issuance of warrant	8,306								8,306							8,306
Issuance of pre-funded warrants, net of costs of $155	2,343								2,343							2,343
Stock-based compensation cost	5,576								5,576							5,576
Vesting of restricted stock units	750								750							750
Vesting of restricted stock units, shares					7,058
Treasury stock repurchase	(272)														$ (272)	(272)
Treasury stock repurchase, shares															(1,282)
Net loss	(104,423)												(103,427)			(103,427)				(996)
Other comprehensive gain, net of tax	1,374													1,374		1,374
Ending balance at Dec. 31, 2022	$ (24,181)				$ 9				$ 1,017,194				$ (1,016,839)	$ 887	$ (7,757)	$ (6,506)				$ (17,675)
Ending balance, shares at Dec. 31, 2022					8,711,696										(84,928)